<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MILLIPRED - prednisolone tablet </strong><br>Laser Pharmaceuticals, LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>Description Section Rx Only</h1>
<p class="First">MILLIPREDtm TABLETS (PREDNISOLONE TABLETS USP, 5 MG) MILLIPREDtm DP - 6-DAY TABLET DOSE PACK (PREDNISOLONE TABLETS USP, 5 MG) MILLIPREDtm DP -12-DAY TABLET DOSE PACK (PREDNISOLONE TABLETS USP, 5 MG) RX ONLY<br><br>DESCRIPTION GLUCOCORTICOIDS ARE ADRENOCORTICAL STEROIDS, BOTH NATURALLY OCCURRING AND SYNTHETIC, WHICH ARE READILY ABSORBED FROM THE GASTROINTESTINAL TRACT. PREDNISOLONE IS A WHITE CRYSTALLINE POWDER, VERY SLIGHTLY SOLUBLE IN WATER. IT IS DESIGNATED CHEMICALLY AS PREGNA-1,4-DIENE-3,20-IONE,11,17,21-TRIHYDROXY-, (11B)-. THE STRUCTURAL FORMULA IS REPRESENTED BELOW:</p>
<br><p><img alt="CHEMICAL FORMULA" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b8fadaec-9985-4f17-9b2f-b2f6a28cae1c&amp;name=MILLIPRED_chem_image.jpg"></p>
<p>M.W.  360.45<br><br>MILLIPRED AND MILLIPRED DP TABLETS CONTAIN THE FOLLOWING INACTIVE INGREDIENTS: ANHYDROUS LACTOSE, COLLOIDAL SILICON DIOXIDE, CROSPOVIDONE, D AND C YELLOW NO 10, DOCUSATE SODIUM, FD AND C YELLOW NO 6, MAGNESIUM STEARATE AND SODIUM BENZOATE.<br></p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">NATURALLY OCCURRING GLUCOCORTICOIDS (HYDROCORTISONE AND CORTISONE), WHICH ALSO HAVE SALT-RETAINING PROPERTIES, ARE USED AS REPLACEMENT THERAPY IN ADRENOCORTICAL DEFICIENCY STATES. PREDNISOLONE IS PRIMARILY USED FOR ITS POTENT ANTI-INFLAMMATORY EFFECTS IN DISORDERS OF MANY ORGAN SYSTEMS. GLUCOCORTICOIDS CAUSE PROFOUND AND VARIED METABOLIC EFFECTS. IN ADDITION, THEY MODIFY THE BODY'S IMMUNE RESPONSES TO DIVERSE STIMULI.<br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USES SECTION</h1>
<p class="First">INDICATIONS AND USES:<br><br>1. <span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">ENDOCRINE DISORDERS</span>: PRIMARY OR SECONDARY ADRENOCORTCAL INSUFFICIENCY (HYDROCORTISONE OR CORTISONE IS THE FIRST CHOICE; SYNTHETIC ANALOGS MAY BE USED IN CONJUNCTION WITH MINERALCORTICOIDS WHERE APPLICABLE; IN INFANCY MINERALCORTICOIDS SUPPLEMENTATION IS OF PARTICULAR IMPORTANCE). CONGENITAL ADRENAL <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">HYPERPLASIA</span> NONSUPPURATIVE <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">THYROIDITIS</span>. <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">HYPERCALCEMIA</span> ASSOCIATED WITH CANCER<br><br>2. RHEUMATIC DISORDERS. AS ADJUNCTIVE THERAPY FOR SHORT TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXCERBATION) IN:<br><br> <span class="product-label-link" type="condition" conceptid="81931" conceptname="Psoriasis with arthropathy">PSORIATIC ARTHRITIS</span> <br><br><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">RHEUMATOID ARTHRITIS</span>: INCLUDING <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">JUVENILE RHEUMATOID ARTHRITIS</span> (SELECTED CASES MAY REQUIRE LOW-DOSE MAINTENANCE THERAPY)<br><br>ANKYLOSING SPONDYLITIS    ACUTE AND SUBACUTE BURSITIS    ACUTE AND NONSPECIFIC TENDSYNOVITIS    ACUTE GOUTY ARTHRITIS    POST-TRAMATIC OSTEOARTHRITIS    <span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">SYNOVITIS</span> OF <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">OSTEOARTHRITIS</span> <span class="product-label-link" type="condition" conceptid="4249170" conceptname="Epicondylitis">EPICONDYLITIS</span><br><br>3. COLLAGEN DISEASES. DURING AN EXCERBATION OR AS A MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC LUPUS ERYTHERMATOSUS    ACUTE RHEUMATIC CARDITIS    SYSTEMIC DERMATOMYSITIS (POLY-<span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">MYOSITIS</span>).<br><br>4. DERMATOLOGIC DISEASES<br><br>PEMPHIGUS    <span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">BULLOUS DERMATITIS</span> HERPETIFORMIS    SEVERE <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">ERYTHEMA MULTIFORME</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">STEVENS-JOHNSON SYNDROME</span>);    EXFOLIATIVE DERMATITIS    <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">MYCOSIS</span> FUNGOIDES    SEVERE PSORIASIS    SEVERE <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">SEBORRHEIC DERMATITIS</span>.<br><br>5. ALLERGIC STATES. CONTROL OF SEVERE OR INCAPACITATING ALLERGIC CONDITIONS INTRACTABLE TO ADEQUATE TRIALS OF CONVENTIONAL TREATMENT:<br><br>SEASONAL OR PERENNIAL ALLERGIC RHINITIS    SERUM SICKNESS    CONTACT DERMATITIS    BRONCHIAL ASTHMA    <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">ATOPIC</span> DERMATITIS    <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">DRUG HYPERSENSITIVITY</span> REACTIONS<br><br>6. OPTHALMIC DISEASES. SEVERE  ACUTE AND CHRONIC ALLERGIC AND INFLAMMATORY PROCESSES INVOLVING THE EYE AND ITS ADNEXA SUCH AS:<br><br>ALLERGIC CONJUNCTIVITIS    KERATITIS    ALLERGIC CORNEAL MARGINAL ULCERS    <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">HERPES ZOSTER</span> OPHTHALMICUS    <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">IRITIS</span> AND IRIDOCYCLITIS    CHORIORENTINTIS    ANTERIOR SEGMENT INFLAMMATION     DIFFUSE POSTERIOR <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">UVEITIS</span> AND CHOROIDTIS    OPTIC NEURITIS    SYMPATHETIC OPHTHALMIA<br><br>7. RESPIRATORY DISEASES<br><br>SYMPTOMATIC SARCOIDOSIS    LOEFFLER'S SYNDROME NOT MANAGED BY OTHER MEANS    BERYLLIOSIS   FULMINATING OR DISSEMINATED <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">PULMONARY TUBERCULOSIS</span> WHEN USED CONCURRENTLY WITH APPROPRIATE ANTITUBERCULOUS CHEMOTHERAPY.    <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">ASPIRATION PNEUMONIA</span><br><br>8. HEMATOLOGIC DISORDERS<br><br><span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">IDIOPATHIC THROMBOCYTOPENIC PURPURA</span> IN ADULTS    SECONDARY <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">THROMBOCYTOPENIA</span> IN ADULTS    ACQUIRED (AUTOIMMUNE) HEMOLYTIC ANEMIA    ERYTHROBLASTOPENIA (RBC <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">ANEMIA</span>)    CONGENITAL (ERYTHROID) <span class="product-label-link" type="condition" conceptid="4218974" conceptname="Hypoplastic anemia">HYPOPLASTIC ANEMIA</span><br><br>9. NEOPLASTIC DISEASES. FOR PALLIATIVE MANAGEMENT OF:    <br><br><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">LEUKEMIAS</span> AND <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">LYMPHOMAS</span> IN ADULTS    <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">ACUTE LEUKEMIA</span> OF CHILDHOOD<br><br>10. EDEMATOUS STATES.  TO INDUCE A <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">DIURESIS</span> OR REMISSION OF <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">PROTEINURIA</span> IN THE NEPHROIC SYNDROME, WITHOUT <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">UREMIA</span>, OF THE IDIOPATHIC TYPE OR THAT DUE TO <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">LUPUS ERYTHEMATOSUS</span>.<br><br>11. GASTROINTESTIONAL DISEASES.<br><br>TO TIDE THE PATIENT OVER A CRITICAL PERIOD OF THE DISEASE IN:<br><br>ULCERATIVE COLITIS    <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">REGIONAL ENTERITIS</span><br><br>12. NERVOUS SYSTEM.  ACUTE EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">MULTIPLE SCLEROSIS</span>.<br><br>13. MISCELLANEOUS<br><br>TUBERCULOUS <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">MENINGITIS</span> WITH SUBARACHNOID BLOCK OR IMPENDING BLOCK WHEN USED CONCURRENTLY WITH APPROPRIATE ANTITUBERCULOUS CHEMOTHERAPY    TRICHINOSIS WITH NEUROLOGIC OR MYOCARDIAL INVOLVEMENT<br></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">SYSTEMIC <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">FUNGAL INFECTIONS</span><br></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">PERSONS WHO ARE ON DRUGS WHICH SUPPRESS THE IMMUNE SYSTEM ARE MORE SUSCEPTIBLE TO <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> THAN HEALTHY INDIVIDUALS.<br><br><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">CHICKENPOX</span> AND <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">MEASLES</span>, FOR EXAMPLE, CAN HAVE A MORE SERIOUS OR EVEN FATAL COURSE IN NON-IMMUNE CHILDREN OR ADULTS ON CORTICOSTEROIDS. iN SUCH CHILDREN OR ADULTS WHO HAVE NOT HAD THESE DISEASES, PARTICULAR CARE SHOULD BE TAKEN TO AVOID EXPOSURE.<br><br>HOW THE DOSE, ROUTE AND DURATION OF CORTICOSTEROID ADMINISTRATION AFFECTS THE RISK OF DEVELOPING A DISSEMINATED <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTION</span> IS NOT KNOWN. THE CONTRIBUTION OF THE UNDERLYING DISEASE AND/OR PRIOR CORTICOSTEROID TREATMENT TO THE RISK IS ALSO NOT KNOWN.<br><br>IF EXPOSED TO THE CHICKEN POX, PROPHYLAXIS WITH <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">VARICELLA ZOSTER</span> IMMUNE GLOBULIN (VZIG) MAY BE INDICATED. IF EXPOSED TO <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">MEASLES</span>, PROPHYLAXIS WITH POOLED INTRAMUSCULAR IMMUNOGLOBULIN (IG) MAY BE INDICATED. (SEE THE RESPECTIVE PACKAGE INSERTS FOR COMPLETE VZIG AND IG PRESCRIBING INFORMATION.) IF <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">CHICKENPOX</span> DEVELOPS, TREATMENT WITH ANTIVIRAL AGENTS MAY BE CONSIDERED.<br><br>IN PATIENTS ON CORTICOSTEROID THERAPY SUBJECTED TO UNUSUAL STRESS INCREASED DOSAGE OF RAPIDLY ACTING CORTICOSTEROIDS BEFORE, DURING, AND AFTER THE STRESSFUL SITUATION IS INDICATED. CORTICOSTEROIDS MAY MASK SOME SIGNS OF <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTION</span>, AND NEW <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> MAY APPEAR DURING THEIR USE. THERE MAY BE DECREASED RESISTANCE AND INABILITY TO LOCALIZE <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTION</span> WHEN CORTICOSTEROIDS ARE USED. PROLONGED USE OF CORTICOSTEROIDS MAY PRODUCE <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">POSTERIOR SUBCAPSULAR CATARACTS</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">GLAUCOMA</span> WITH POSSIBLE DAMAGE TO THE OPTIC NERVES, AND MAY ENHANCE THE ESTABLISHMENT OF SECONDARY OCULAR <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> DUE TO FUNGI OR VIRUSES.<br></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6"></a><p></p>
<h1>USAGE IN PREGNANCY</h1>
<p class="First">SINCE ADEQUATE HUMAN PRODUCTION STUDIES HAVE NOT BEEN DONE WITH CORTICOSTEROIDS, THE USE OF THESE DRUGS IN PREGNANCY, NURSING MOTHERS OR WOMEN OF CHILDBEARING POTENTIAL REQUIRES THAT THE POSSIBLE BENEFITS OF THE DRUG BE WEIGHED AGAINST THE POTENYIAL HAZARDS TO THE MOTHER AND EMBRYO OR FETUS. INFANTS BORN OF MOTHER WHO HAVE RECEIVED SUBSTANTIAL DOSES OF CORTICOSTERIODS DURING PREGNANCY, SHOULD BE CAREFULLY OBSERVED FOR SIGNS OF <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">HYPOADRENALISM</span>.<br><br>AVERAGE AND LARGE DOSES OF HYDROCORTISONE OR CORTISONE CAN CAUSE ELEVATION OF BLOOD PRESSURE, SALT AND <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">WATER RETENTION</span>, AND INCREASED EXCRETION OF POTASSIUM. THESE EFFECTS ARE LESS LIKELY TO OCCUR WITH SYNTHETIC DERIVATIVES EXCEPT WHEN USED IN LARGE DOSES. DIETARY SALT RESTRICTION AND POTASSIUM SUPPLEMENTATION MAY BE NECESSARY. ALL CORTICOSTEROIDS INCREASE CALCIUM EXCRETION.<br><br>WHILE ON CORTICOSTEROID THERAPY PATIENTS SHOULD NOT BE VACCINATED AGAINST <span class="product-label-link" type="condition" conceptid="134573" conceptname="Smallpox">SMALLPOX</span>. OTHER IMMUNIZATION PROCEDURES SHOULD NOT BE UNDERTAKEN IN PATIENTS WHO ARE ON CORTICOSTEROIDS, ESPECIALLY ON HIGH DOSE, BECAUSE OF POSSIBLE HAZARDS OF NEUROLOGICAL COMPLICATIONS AND A LACK OF ANTIBODY RESPONSE.<br><br>THE USE OF PREDNISONE IN ACTIVE <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">TUBERCULOSIS</span> SHOULD BE RESTRICTED TO THOSE CASES OF FULMINATING OR <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">DISSEMINATED TUBERCULOSIS</span> IN WHICH THE CORTICOSTEROID IS USED FOR THE MANAGEMENT OF THE DISEASE IN CONJUNCTION WITH AN APPROPRIATE ANTITUBERCULOUS REGIMEN.<br><br>IF CORTICOSTEROIDS ARE INDICATED IN PATIENTS WITH LATENT <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">TUBERCULOSIS</span> OR TUBERCULIN REACTIVITY, CLOSE OBSERVATION IS NECESSARY AS REACTIVATION OF THE DISEASE MAY OCCUR.<br><br>DURING PROLONGED CORTICOSTEROID THERAPY, THESE PATIENTS SHOULD RECEIVE CHEMOPROPHYLAXIS.<br></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS
INFORMATION FOR PATIENTS</h1>
<p class="First">PERSONS WHO ARE ON IMMUNOSUPPRESSANT DOSES OF CORTICOSTEROIDS SHOULD BE WARNED TO AVOID EXPOSURE TO <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">CHICKENPOX</span> OR <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">MEASLES</span>. PATIENTS SHOULD ALSO BE ADVISED THAT IF THEY ARE EXPOSED, MEDICAL ADVICE SHOULD BE SOUGHT WITHOUT DELAY.<br><br>DRUD-INDUCED <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">SECONDARY ADRENOCORTICAL INSUFFICIENCY</span> MAY BE MINIMIZED BY GRADUAL REDUCTION OF DOSAGE. THIS TYPE OF RELATIVE INSUFFICIENCY MAY PERSIST FOR MONTHS AFTER DISCONTINUATION OF THERAPY; THEREFORE, IN ANY SITUATION OF STRESS OSSURING DURING THAT PERIOD, HORMONE THERAPY SHOULD BE REINSTITUTED. SINCE MINERALO-CORTICOID SECRETION MAY BE IMPAIRED, SALT AND/OR A MINERALOCORTICOID SHOULD BE ADMINISTERED CONCURRENTLY. THERE IS AN ENHANCED EFFECT OF CORTICOSTEROIDS ON PATIENTS WITH <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">HYPOTHYROIDISM</span> AND IN THOSE WITH CIRRHOSIS. CORTICOSTEROIDS SHOULD BE USED CAUTIOUSLY IN PATIENTS WITH OCCULAR HERPES SIMPLEX BECAUSE OF POSSIBLE <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">CORNEAL PERFORATION</span>.<br><br>THE LOWEST POSSIBLE  DOSE OF CORTIOCSTEROIDS SHOULD BE USED TO CONTROL THE CONDITION UNDER TREATMENT, AND WHEN REDUCTION IN DOSE IS POSSIBLE, THE REDUCTION SHOULD BE GRADUAL. PSYCHIC DERANGEMENTS MAY APPEAR  WHEN CORTICOSTEROIDS ARE USED, RANGING FROM <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">EUPHORIA</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">INSOMNIA</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">MOOD SWINGS</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">PERSONALITY CHANGES</span>, AND SEVERE <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> TO FRANK <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOTIC</span> MANIFESTATIONS. ALSO, EXISTING <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">EMOTIONAL INSTABILITY</span> OR <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOTIC</span> TENDENCIES MAY BE AGGRAVATED BY CORTICOSTEROIDS.<br><br>ASPIRIN SHOULD BE USED CAUTIOUSLY IN CONJUNCTION WITH CORTICOSTEROIDS IN HYPOTHROMBINEMIA.<br><br>STEROIDS SHOULD BE USED WITH CAUTION IN NONSPECIFIC <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ULCERATIVE COLITIS</span>, IF THERE IA S PROBABILITY OF IMPENDING PERFORATION, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">ABSCESS</span> OR OTHER PYOGENIC <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTION</span>; <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">DIVERTICULITIS</span>; FRESH INTESTINAL ANASTOMOSES; ACTIVE OR LATENT <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">PEPTIC ULCER</span>; <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">RENAL INSUFFICIENCY</span>; <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">HYPERTENSION</span>; <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">OSTEOPOROSIS</span> AND <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">MYASTHENIA GRAVIS</span>.<br><br>GROWTH AND DEVELOPMENT OF INFANTS AND CHILDREN ON PROLONGED CORTICOSTEROID THERAPY SHOULD BE CAREFULLY OBSERVED.<br><br>ALTHOUGH CONTROLLED CLINICAL TRIALS HAVE SHOWN CORTICOSTEROIDS TO BE EFFECTIVE IN SPEEDING THE RESOLUTION OF ACUTE EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">MULTIPLE SCLEROSIS</span> THEY DO NOT SHOW THAT THEY AFFECT THE ULTIMATE OUTCOME OR NATURAL HISTORY OF THE DISEASE. THE STUDIES DO SHOW THAT THE RELATIVELY HIGH DOSES OF CORTICOSTEROIDS ARE NECESSARY TO DEMONSTRATE A SIGNIFICANT EFFECT. (SEE DOSAGE AND ADMINISTRATION SECTION.)<br><br>SINCE COMPLICATIONS OF TREATMENT WITH GLUCOCORTICOIDS ARE DEPENDENT ON THE SIZE OF THE DOSE AND THE DURATION OF TREATMENT, A RISK/BENEFIT DECISION MUST BE MADE IN EACH INDIVIDUAL CASE AS TO DOSE AND DURATION OF TREATMENT AND AS TO WHETHER DAILY OR INTERMITTENT THERAPY SHOULD BE USED.<br></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">FLUID AND <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">ELECTROLYTE DISTURBANCES</span> <br><br><span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">SODIUM RETENTION</span>. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">FLUID RETENTION</span>. <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span> IN SUSCEPTIBLE PATIENTS. POTASSIUM LOSS. <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">HYPOKALEMIC ALKALOSIS</span>. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">HYPERTENSION</span>.<br><br>MUSCULOSKELETAL<br><br><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">MUSCLE WEAKNESS</span>. <span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">STEROID MYOPATHY</span>. LOSS OF <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">MUSCLE MASS</span>. <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">OSTEOPOROSIS</span>. VERTEBRAL <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">COMPRESSION FRACTURES</span>. <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">ASEPTIC NECROSIS</span> OF FEMORAL AND HUMERAL HEADS. PATHOLOGIC <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">FRACTURE</span> OF LONG BONES.<br><br>GASTROINTESTINAL <br><br><span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">PEPTIC ULCER</span> WITH POSSIBLE PERFORATION AND <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">HEMORRHAGE</span>. <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">PANCREATITIS</span>. ABDOMINAL <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">DISTENTION</span>. ULCERATIVE <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">ESOPHAGITIS</span>.<br><br>DERMATOLOGIC<br><br>IMPAIRED <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">WOUND</span> HEALING. THIN FRAGILE SKIN. <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">PETECHIAE</span> AND SCCHYMOSES. FACIAL <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">ERYTHEMA</span>. INCREASED <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">SWEATING</span>. MAY SUPRESS REACTIONS TO SKIN TESTS.<br><br>NEUROLOGICAL <br><br><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">CONVULSIONS</span>. INCREASED INTERCRANIAL PRESSURE WITH <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">PAPILLEDEMA</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">PSEUDOTUMOR CEREBRI</span>) USUALLY AFTER TREATMENT. <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">VERTIGO</span>. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">HEADACHE</span>.<br><br>ENDOCRINE<br><br>MENSTRUAL IRREGULARITIES. DEVELOPMENT OF <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">CUSHINGOID</span> STATE. SUPPRESSION OF GROWTH IN CHILDREN. SECONDARY ADRENOCORTICAL AND PITUITARY UNRESPONSIVENESS, PARTICULARLY IN TIMES OF STRESS, AS IN <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">TRAUMA</span>, SURGERY, OR ILLNESS. DECREASED CARBOHYDRATE TOLERANCE. MANIFESTATIONS OF <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">LATENT DIABETES</span> MELITUS. INCREASED REQUIREMENTS FOR INSULIN OR ORAL HYPOGLYCEMIC AGENTS IN <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">DIABETES</span>.<br><br>OPHTHALMIC<br><br><span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">POSTERIOR SUBCAPSULAR CATARACTS</span>. <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">INCREASED INTRAOCULAR PRESSURE</span>. <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">GLAUCOMA</span>. <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">EXOPHTHALMOS</span>.<br><br>METABOLIC<br><br>NEGATIVE NITROGEN BALANCE DUE TO PROTEIN CATABOLISM.<br></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">THE INITIAL DOSAGE OF MILLIPRED AND MILLIPRED DP TABLETS MAY VARY FROM 5MG TO 60MG PER DAY DEPENDING ON THE SPECIFIC DISEASE ENTITY BEING TREATED. IN SITUATIONS OF LESS SEVERITY, LOWER DOSES WILL GENERALLY SUFFICE, WHILE IN SELECTED PATIENTS HIGHER INITIAL DOSES MAY BE REQUIRED. THE INITIAL DOSE SHOULD BE MAINTAINED OR ADJUSTED UNTIL A SATISFACTORY RESPONSE IS NOTED. IF AFTER A REASONABLE PERIOD OF TIME THERE IS A LACK OF SATISFACTORY CLINICAL RESPONSE, PREDNISOLONE SHOULD BE DISCONTINUED AND THE PATIENT TRANSFERRED TO OTHER APPROPRIATE THERAPY.<br><br>IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT.<br><br>AFTER A FAVORABLE RESPONSE IS NOTED, THE PROPER MAINTENANCE DOSAGE SHOULD BE DETERMINED BY DECREASING THE INITIAL DRUG DOSE IN SMALL INCREMENTS AT APPROPRIATE TIME INTERVALS UNTIL THE LOWEST DOSAGE WHICH WILL MAINTAIN AN ADEQUATE CLINICAL RESPONSE IS REACHED. IT SHOULD BE KEPT IN MIND THAT CONSTANT MONITORING IS NEEDED IN REGARDS TO DRUG DOSAGE. INCLUDED IN THE SITUATIONS WHICH MAY MAKE DOSAGE ADJUSTMENTS NECESSARY ARE THE CHANGES IN CLINICAL STATUS SECONDARY TO REMISSIONS OR EXACERBATIONS IN THE DISEASE PROCESS, THE PATIENT'S INDIVIDUAL DRUG RESPONSIVENESS, AND THE EFFECT OF PATIENT EXPOSURE TO STRESSFUL SITUATIONS NOT DIRECTLY RELATED TO THE DISEASE ENTITY UNDER TREATMENT; IN THIS LATER SITUATION IT MAY BE NECESSARY TO INCREASE THE DOSAGE OF PREDNISOLONE FOR A PERIOD OF TIME CONSISTENT WITH THE PATIENT'S CONDITION. IF AFTER LONG-TERM THERAPY THE DRUG IS TO BE STOPPED, IT IS RECOMMENDED THAT IT BE WITHDRAWN GRADUALLY RATHER THAN ABRUPTLY.<br><br>ALTERNATE-DAY THERAPY<br><br>ALTERNATE-DAY THERAPY IS A CORTICOSTEROID DOSING REGIMEN IN WHICH TWICE THE USUAL DAILY DOSE OF CORTICOID IS ADMINISTERED EVERY OTHER MORNING. THE PURPOSE OF THIS MODE OF THERAPY IS TO PROVIDE THE PATIENT REQUIRING LONG-TERM PHARMACOLOGIC DOSE TREATMENT WITH THE BENEFICIAL EFFECTS OF CORTICOIDS WHILE MINIMIZING CERTAIN UNDESIRABLE EFFECTS, INCLUDING PITUITARYADRENAL SUPPRESSION, THE <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">CUSHINGOID</span> STATE, CORTICOID WITHDRAWAL SYMPTOMS, AND <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">GROWTH SUPPRESSION</span> IN CHILDREN.<br><br>THE RATIONALE FOR THIS TREATMENT SCHEDULE IS BASED ON TWO MAJOR PREMISES; (a) THE ANTI-INFLAMMATORY OR THERAPEUTIC EFFECT OF CORTICOIDS PERSISTS LONGER THAN THEIR PHYSICAL PRESENCE AND METABOLIC EFFECTS AND (b) ADMINISTRATION OF THE CORTICOSTEROID EVERY OTHER MORNING ALLOWS FOR RE-ESTABLISHMENT OF MORE NEARLY NORMAL HYPOTHALAMIC-PITUTARY-ADRENAL (HPA) ACTIVITY ON THE OFF-STEROID DAY.<br><br>A BRIEF REVIEW OF THE HPA PHYSIOLOGY MAY BE HELPFUL IN UNDERSTANDING THIS RATIONAL. ACTING PRIMARILY THROUGH THE HYPOTHALAMUS A <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">FALL</span> IN FREE CORTISOL STIMULATES THE PITUITARY GLAND TO PRODUCE INCREASING AMOUNTS OF CORTICOTROPIN (ACTH) WHILE A RISE IN FREE CORTISOL INHIBITS ACTH SECRETION. NORMALLY THE HPA SYSTEM IS CHARACTERIZED BY DIURNAL (CIRCADIAN) RHYTHM. SERUM LEVELS OF ACTH RISE FROM A LOW POINT ABOUT 10 p.m. TO A PEAK LEVEL ABOUT 6 a.m. INCREASING LEVELS OF ACTH STIMULATE ADRENOCORTICAL ACTIVITY RESULTING IN A RISE IN PLASMA CORTISOL WITH A MAXIMAL LEVELS OCCURING BETWEEN 2 a.m. AND 8 a.m. THIS RISE IN CORTISOL DAMPENS ACTH PRODUCTION AND IN TURN ADRENOCORTICAL ACTIVITY. THERE IA A GRADUAL <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">FALL</span> IN PLASMA CORTICOIDS DURING THE DAY, THE LOWEST LEVELS OCCURRING ABOUT MIDNIGHT. THE DIURNAL RHYTHM OF THE HPA AXIS IN CUSHING'S DISEASE, A SYNDROME OF ADRENOCORTICAL HYPERFUNCTION CHARACTERIZED BY <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">OBESITY</span> WITH CENTRIPETAL FAT DISTRIBUTION, THINNING OF THE SKIN WITH EASY BRUISABILITY, <span class="product-label-link" type="condition" conceptid="78236" conceptname="Muscle atrophy">MUSCLE WASTING</span> AND <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">WEAKNESS</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">HYPERTENSION</span>, <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">LATENT DIABETES</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">OSTEOPOROSIS</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">ELECTROLYTE IMBALANCES</span>, ETC. THE SAME CLINICAL FINDINGS OF <span class="product-label-link" type="condition" conceptid="438123" conceptname="Adrenocortical hyperfunction">HYPERADRENOCORTICISM</span> MAY BE NOTED DURING THE LONG-TERM PHARMACOLOGIC DOSE CORTICOID THERAPY ADMINISTERED IN CONVENTIONAL DAILY DIVIDED DOSES. IT WOULD APPEAR THEN, THAT A DISTURBANCE IN THE DIURNAL CYCLE WITH MAINTENANCE OF ELEVATED CORTICOID VALUES DURING THE NIGHT MAY PLAY A SIGNIFICANT ROLE IN THE DEVELOPMENT OF UNDESIRABLE CORTICOID EFFECTS. ESCAPE FROM THESE CONSTANTLY ELEVATED PLASMA LEVELS FOR EVEN SHORT PERIODS OF TIME MAY BE INSTRUMENTAL IN PROTECTING AGAINST UNDESIRABLE PHARMACOLOGIC EFFECTS.<br><br>DURING CONVENTIONAL PHARMACOLOGIC DOSE CORTICOSTEROID THERAPY, ACTH PRODUCTION IS INHIBITED WITH SUBSEQUENT SUPPRESSION OF CORTISOL PRODUCTION BY THE ADRENAL CORTEX. RECOVERY TIME FOR NORMAL HPA ACTIVITY IS VARIABLE DEPENDING UPON THE DOSE AND DURATION OF TREATMENT.<br><br>DURING THIS TIME THE PATIENT IS VULENERABLE TO ANY STRESSFUL SITUATION.<br><br>ALTHOUGH IT HAS BEEN SHOWN THAT THERE IS CONSIDERABLY LESS ADRENAL SUPPRESSION FOLLOWING A SINGLE MORNING DOSE OF PREDNISOLONE (10 MG) AS OPPOSED TO A QUARTER OF THAT DOSE ADMINISTERED EVERY 6 HOURS, THERE IS EVIDENCE THAT SOME SUPPRESSIVE EFFECT ON ADRENAL ACTIVITY MAY BE CARRIED OVER INTO THE FOLLOWING DAY WHEN PHARMACOLOGIC DOSES ARE USED. FURTHER, IT HAS BEEN SHOWN THAT A SINGLE DOSE OF A CERTAIN CORTICOSTEROIDS WILL PRODUCE ADRENOCORTICAL SUPPRESSION FOR TWO OR MORE DAYS. OTHER CORTICOIDS, INCLUDING METHYLPREDNISOLONE, HYDROCORTISONE, PREDNISONE, AND PREDNISOLONE, ARE CONSIDERED TO BE SHORT ACTING (PRODUCING ADRENOCORTICAL SUPPRESSION FOR 1 1/4 DAYS TO 1 1/2 DAYS FOLLOWING A SINGLE DOSE) AND THUS ARE RECOMMENDED FOR ALTERNATE-DAY THERAPY.<br><br>THE FOLLOWING SHOULD BE KEPT IN MIND WHEN CONSIDERING ALTERNATE-DAY THERAPY:<br><br>1. BASIC PRINCIPLES AND INDICATIONS FOR CORTICOSTEROID THERAPY SHOULD APPLY. THE BENEFITS OF ALTERNATE-DAY THERAPY SHOULD NOT ENCOURAGE THE INDISCRIMINATE USE OF STEROIDS.<br><br>2. ALTERNATE-DAY THERAPY IS A THERAPEUTIC TECHNIQUE PRIMARILY DESIGNED FOR PATIENTS IN WHOM LONG-TERM PHARMACOLOGIC CORTICOID THERAPY IS ANTICIPATED.<br><br>3. IN LESS SEVERE DISEASE PROCESSES IN WHICH CORTICOID THERAPY IS INDICATED, IT MAY BE POSSIBLE TO INITIATE TREATMENT WITH ALTERNATE-DAY THERAPY. MORE SEVERE DISEASE STATES USUALLY WILL REQUIRE DAILY DIVIDED HIGH DOSE THERAPY FOR INITIAL CONTROL OF THE DISEASE PROCESS. THE INITIAL SUPPRESSIVE DOSE LEVEL SHOULD BE CONTINUED UNTIL SATISFACTORY CLINICAL RESPONSE IS OBTAINED, USUALLY FOUR TO TEN DAYS IN THE CASE OF MANY ALLERGIC AND COLLAGEN DISEASES. IT IS IMPORTANT TO KEEP THE PERIOD OF INITIAL SUPPRESSIVE DOSE AS BRIEF AS POSSIBLE PARTICULARLY WHEN SUBSEQUENT USE OF ALTERNATE-DAY THERAPY IS INTENDED.<br><br>ONCE CONTROL HAS BEEN ESTABLISHED, TWO COURSES ARE AVAILABLE: (a) CHANGE TO ALTERNATE-DAY THERAPY AND THEN GRADUALLY REDUCE THE AMOUNT OF CORTICOID GIVEN EVERY OTHER DAY, OR (b) FOLLOWING THE COURSE OF THE DISEASE PROCESS, REDUCE THE DAILY DOSE OF CORTICOID TO THE LOWEST EFFECTIVE LEVEL AS RAPIDLY AS POSSIBLE AND THEN CHANGE OVER TO ALTERNATE-DAY SCHEDULE. THEORETICALLY, COURSE (a) MAY BE PREFERABLE. <br><br>4. BECAUSE OF THE ADVANTAGES OF ALTERNATE-DAY THERAPY, IT MAY BE DESIRABLE TO TRY PATIENTS ON THIS FORM OF THERAPY WHO HAVE BEEN ON DAILY CORTICOIDS FOR LONG PERIODS OF TIME (E.G. PATIENTS WITH <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">RHEUMATOID ARTHRITIS</span>). SINCE THESE PATIENTS MAY ALREADY HAVE A SUPPRESSED PA AXIS, ESTABLISHING THEM ON ALTERNATE-DAY THERAPY MAY BE DIFFICULT AND NOT ALWAYS SUCCESSFUL. HOWEVER, IT IS RECOMMENDED THAT REGULAR ATTEMPTS BE MADE TO CHANGE THEM OVER. IT MAY BE HELPFUL TO TRIPLE OR EVEN QUADRUPLE THE DAILY MAINTENANCE DOSE AND ADMINISTER THIS EVERY OTHER DAY RATHER THAN JUST DOUBLING THE DAILY DOSE IF DIFFICULTY IS ENCOUNTERED. ONCE THE PATIENT IS AGAIN CONTROLLED, AN ATTEMPT SHOULD BE MADE TO REDUCE THIS DOSE TO A MINIMUM.<br><br>5. AS INDICATED ABOVE, CERTAIN CORTICOIDS, BECAUSE OF THEIR PROLONGED SUPPRESSIVE EFFECT ON ADRENAL ACTIVITY, ARE NOT RECOMMENDED FOR ALTERNATE-DAY THERAPY (E.G., DEXMETHOSONE AND BETAMETHASONE).<br><br>6. THE MAXIMAL ACTIVITY OF THE ADRENAL CORTEX IS BETWEEN 2 a.m. AND 8 a.m., AND IT IS MINIMAL BETWEEN 4 p.m. AND MIDNIGHT. EXOGENOUS CORTICOSTEROIDS SUPPRESS ADRENALCORTICAL ACTIVITY THE LEAST, WHEN GIVEN AT THE TIME OF MAXIMAL ACTIVITY (a.m.).<br><br>7. IN USING ALTERNATE-DAY THERAPY IT IS IMPORTANT, AS IN ALL THERAPEUTIC SITUATIONS, IN INDIVIDUALIZE AND TAILOR THE THERAPY TO EACH PATIENT. COMPLETE CONTROL OF SYMPTOMS WILL NOT BE POSSIBLE IN ALL PATIENTS. AN EXPLANATION OF THE BENEFITS OF ALTERNATE-DAY THERAPY WILL HELP THE PATIENT TO UNDERSTAND AND TOLERATE THE POSSIBLE FLARE-UP IN SYMPTOMS WHICH MAY OCCUR IN THE LATER PART OF THE OFF-STEROID DAY.<br><br>OTHER SYMPTOMATIC THERAPY MAY BE ADDED OR INCREASED AT THIS TIME IF NEEDED.<br><br>8. IN THE EVENT OF AN ACUTE FLARE-UP OF THE DISEASE PROCESS, IT MAY BE NECESSARY TO RETURN TO A FULL SUPPRESSIVE DAILY DIVIDED CORTICOID DOSE FOR CONTROL. ONCE CONTROL IS AGAIN ESTABLISHED, ALTERNATE-DAY THERAPY MAY BE REINSTITUTED.<br><br>9. ALTHOUGH MANY OF THE UNDESIRABLE FEATURES OF CORTICOSTEROID THERAPY CAN BE MINIMIZED BY ALTERNATE-DAY THERAPY, AS IN ANY THERAPEUTIC SITUATION, THE PHYSICIAN MUST CAREFULLY WEIGH THE BENEFIT-RISK RATIO FOR EACH PATIENT WITH WHOM CORTICOID THERAPY IS BEING CONSIDERED.<br></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">MILLIPRED AND MILLIPRED DP TABLETS (PREDNISOLONE TABLETS USP 5 MG) ARE SCORED, ROUND, PEACH TABLETS IMPRINTED DAN DAN 5059 SUPPLIED IN BOTTLES OF 100 (NDC 16477-505-01), A UNIT OF USE <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK OF 21 TABLETS (NDC 16477-505-21) AND A UNIT OF USE <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK OF 48 TABLETS (NDC 16477-505-48) RESPECTIVELY.<br><br>DISPENSE IN A WELL-CLOSED CONTAINER WITH A CHILD-RESISTANT CLOUSURE.<br><br>STORE AT 20 DEGREES 20 - 25 DEGREES C (68 - 77 DEGREES F). [SEE USP CONTROLLED ROOM TEMPERATURE.]<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>PACKAGE INSERT AND INFORMATION</h1>
<p class="First">MANUFACTURED BY: WATSON PHARMA PRIVATE LIMITED VERNA, SALCETTE Goa 403 722 INDIA<br><br>DISTRIBUTED BY: LASER PHARMACEUTICALS, LLC GREENVILLE, SC 29615<br><br>REVISED : 8/2011   0811A  173415</p>
<br><p><img alt="MILLIPRED LABEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b8fadaec-9985-4f17-9b2f-b2f6a28cae1c&amp;name=Laser_Millipred_5mg_tablets.jpg"></p>
<br><p><img alt="MILLIPRED 12 DAY LABEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b8fadaec-9985-4f17-9b2f-b2f6a28cae1c&amp;name=Laser_Millipred_12Day_pack_.jpg"></p>
<br><p><img alt="MILLIPRED 12 DAY INSERT LABEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b8fadaec-9985-4f17-9b2f-b2f6a28cae1c&amp;name=Laser_Millipred_12Day_pack_label_insert.jpg"></p>
<br><p><img alt="MILLIPRED 6 DAY LABEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b8fadaec-9985-4f17-9b2f-b2f6a28cae1c&amp;name=Laser_Millipred_DP_6Day_pack.jpg"></p>
<p><img alt="MILLIPRED DP 6 DAY INSERT LABEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b8fadaec-9985-4f17-9b2f-b2f6a28cae1c&amp;name=Laser_Millipred_DP_6Day_insert.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MILLIPRED 		
					</strong><br><span class="contentTableReg">prednisolone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16477-505</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PREDNISOLONE</strong> (PREDNISOLONE) </td>
<td class="formItem">PREDNISOLONE</td>
<td class="formItem">5 mg  in 5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DOCUSATE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange (PEACH) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (TABLET) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">DANDAN5059</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16477-505-01</td>
<td class="formItem">5 mg in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16477-505-21</td>
<td class="formItem">5 mg in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:16477-505-48</td>
<td class="formItem">5 mg in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA080354</td>
<td class="formItem">10/01/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Laser Pharmaceuticals, LLC
							(614417132)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Laser Pharmaceuticals, LLC (614417132)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0e6cab4b-a5ad-48ae-9a1a-3c4b28c13f13</div>
<div>Set id: b8fadaec-9985-4f17-9b2f-b2f6a28cae1c</div>
<div>Version: 1</div>
<div>Effective Time: 20111024</div>
</div>
</div> <div class="DistributorName">Laser Pharmaceuticals, LLC</div></p>
</body></html>
